Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells

Journal of Molecular Endocrinology

Volumn 41, Issue 5-6, 2008, Pages 367-377

  Chen, Bin ^a   Wang, Yuanzhong ^a   Kane, Susan E ^a   Chen, Shiuan ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; NUCLEAR RECEPTOR COREPRESSOR; PROTEIN PS2; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; ASSAY; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL NUCLEUS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DRUG EXPOSURE; DRUG SENSITIVITY; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR OCCUPANCY; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTONE ACETYLTRANSFERASES; HUMANS; PROTEIN ISOFORMS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN; TRANSCRIPTION FACTORS;

EID: 57749087753     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/JME-08-0026     Document Type: Article

References (34)

1. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM & Meltzer PS 1997 AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277 965-968.
2. Argiris A, Wang CX, Whalen SG & DiGiovanna MP 2004 Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clinical Cancer Research 10 1409-1420.
3. Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D et al. 2000 HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. Journal of Clinical Oncology 18 3471-3479.
4. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 248-254.
5. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S & Nakshatri H 2001 Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. Journal of Biological Chemistry 276 9817-9824.
6. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME & Shepard HM 1992 Humanization of an anti-p185HER2 antibody for human cancer therapy. PNAS 89 4285-4289.
7. Chan CT, Metz MZ & Kane SE 2005 Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Research and Treatment 91 187-201.
8. Clark AS, West K, Streicher S & Dennis PA 2002 Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Molecular Cancer Therapeutics 1 707-717.
9. Dieras V, Beuzeboc P, Laurence V, Pierga JY & Pouillart P 2001 Interaction between Herceptin and taxanes. Oncology 61 (Suppl 2) 43-49.
10. Dowsett M, Nicholson RI & Pietras RJ 2005 Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Research and Treatment 93 (Suppl 1) S11-S18.
11. Eddy SF, Kane SE & Sonenshein GE 2007 Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate. Cancer Research 67 9018-9023.
12. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H et al. 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270 1491-1494.
13. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT & Arteaga CL 2000 Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Research 60 5887-5894.
14. Lenferink AE, Simpson JF, Shawver LK, Coffey RJ, Forbes JT & Arteaga CL 2000 Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu+MMTV/TGF-α bigenic mite. PNAS 97 9609-9614.
15. Lou G, Li Y, Chen B, Chen M, Chen J, Liao R, Zhang Y, Wang Y & Zhou D 2007 Functional analysis on the 5′-flanking region of human FXR gene in HepG2 cells. Gene 396 358-368.
16. Lu Y, Zi X, Zhao Y, Mascarenhas D & Pollak M 2001 Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). Journal of the National Cancer Institute 93 1852-1857.
17. Moasser MM, Basso A, Averbuch SD & Rosen N 2001 The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Research 61 7184-7188.
18. Nahta R, Yu D, Hung MC, Hortobagyi GN & Esteva FJ 2006 Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice and Oncology 3 269-280.
19. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX & Slamon DJ 1995 HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10 2435-2446.
20. Price-Schiavi SA, Jepson S, Li P, Arango M, Rudland PS, Yee L & Carraway KL 2002 Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. International Journal of Cancer 99 783-791.
21. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK & Osborne CK 2004 Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clinical Cancer Research 10 331S-336S.
22. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H & Schiff R 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. Journal of the National Cancer Institute 96 926-935.
23. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al. 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 707-712.
24. Smith CL, Nawaz Z & O'Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Molecular Endocrinology 11 657-666.
25. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R & Santen RJ 2002 Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Molecular Endocrinology 16 116-127.
26. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV & Cheng JQ 2001 Phosphatidylinositol-3-OH kinase (PI3K)/ AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERα) via interaction between ERα and PI3K. Cancer Research 61 5985-5991.
27. Tang CK, Perez C, Grunt T, Waibel C, Cho C & Lupu R 1996 Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Research 56 3350-3358.
28. Tseng PH, Wang YC, Weng SC, Wang JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M et al. 2006 Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Molecular Pharmacology 70 1534-1541.
29. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M et al. 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 20 719-726.
30. Wang CX, Koay DC, Edwards A, Lu Z, Mor G, Ocal IT & Digiovanna MP 2005 In vitro and in vivo effects of combination of trastuzumab (Herceptin) and Tamoxifen in breast cancer. Breast Cancer Research and Treatment 92 251-263.
31. Wong CW, McNally C, Nickbarg E, Komm BS & Cheskis BJ 2002 Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. PNAS 99 14783-14788.
32. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S & Arteaga CL 2002 Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Research 62 4132-4141.
33. Yang Z, Barnes CJ & Kumar R 2004 Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clinical Cancer Research 10 3621-3628.
34. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-Castori S & Benz CC 2007 Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 7 59.